# US 2025/0188128 A1 · Adeno-associated virus compositions having increased heart enrichment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0188128 A1
- Document ID: US20250188128A1
- Status: Published application
- Kind: A1
- Application number: 18/843,978
- Filed: 2023-03-24
- Published: 2025-06-12
- Earliest claimed: 2022-03-24
- Assignees: Capsida, Inc.
- Applicants: Capsida, Inc.
- Inventors: Brandon G. Wheeler; Xiaojing Shi; Nicholas S. Goeden; Nicholas C. Flytzanis; Troy E. Sandberg
- Web page: https://patentgrep.com/patent/US20250188128A1

## CPC

- C07K 14/005: from viruses
- C12N 15/86: Viral vectors
- C40B 40/08: Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14145: Special targeting system for viral vectors
- C12N 2750/14322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14343: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described herein are compositions and kits comprising recombinant adeno-associated viruses (rAAVs) with increased M transduction enrichment in the heart. The rAAV compositions described herein encapsidate a transgene, such as a therapeutic nucleic acid. Gene therapy using the rAAVs is described. Also described are methods of treating cardiovascular-related diseases and conditions.

## Claims

### Claim 1

An AAV capsid protein comprising a sequence as provided in Tables 1-2 or FIG. 1.

### Claim 2

An AAV capsid comprising an insertion sequence of Formula I
X1-G-G-X2-X3-X4-X5 (I)
wherein X1 is an amino acid selected from G, I, K, L and V; X2 is an amino acid selected from E, G, H, L, N, S and Q; X3 is an amino acid selected from A, F, I, L, P, T and Y; X4 is an amino acid selected from F, L, S and Y; and X5 is an amino acid selected from E, H, I, K, P, S and T.

### Claim 3 (depends on 2)

The AAV capsid protein of claim 2, wherein X1 is I, K or L.

### Claim 4 (depends on 2)

The AAV capsid protein of claim 2, wherein X1 is K.

### Claim 5 (depends on 2)

The AAV capsid protein of claim 2, wherein X1 is I.

### Claim 6 (depends on 2)

The AAV capsid protein of claim 2, wherein X2 is L, H or Q.

### Claim 7 (depends on 2)

The AAV capsid protein of claim 2, wherein X2 is L.

### Claim 8 (depends on 2)

The AAV capsid protein of claim 2, wherein X2 is H.

### Claim 9 (depends on 2)

The AAV capsid protein of claim 2, wherein X3 is I, P or Y.

### Claim 10 (depends on 2)

The AAV capsid protein of claim 2, wherein X4 is an F or L.

### Claim 11 (depends on 2)

The AAV capsid protein of claim 2, wherein X5 is an I or H.

### Claim 12 (depends on 2)

The AAV capsid protein of claim 2, wherein the sequence is selected from KGGLPFI, IGGHYLH, LGGQILI, LGGGFSE, IGGNLLK, KGGETSS, VGGSTYP, and GGGLAST.

### Claim 13

An AAV capsid protein comprising an insertion sequence of Formula II
R-S-X6-X7-X8-X9-X10 (II)
wherein X6 is an amino acid selected from E, G, I, N, Q and T; X7 is an amino acid selected from L, H, Q, S, and T; X8 is an amino acid selected from D, E, H, P, and S; X9 is an amino acid selected from A, F, L, R, S and T; and X10 is an amino acid selected from E, I, M, S and V.

### Claim 14 (depends on 13)

The AAV capsid protein of claim 13, wherein X10 is I, V or M.

### Claim 15 (depends on 13)

The AAV capsid protein of claim 13, wherein X10 is M.

### Claim 16 (depends on 13)

The AAV capsid protein of claim 13, wherein X9 is F or L.

### Claim 17 (depends on 13)

The AAV capsid protein of claim 13, wherein X8 is P or H.

### Claim 18 (depends on 13)

The AAV capsid protein of claim 13, wherein X7 is H or L.

### Claim 19 (depends on 13)

The AAV capsid protein of claim 13, wherein X6 is E or G.

### Claim 20 (depends on 13)

The AAV capsid protein of claim 13, wherein the insertion sequence is selected from RSGHPFV, RSGLHLM, RSELHFI, RSQTSTE, RSISDRV, RSTTDAS, and RSNQESV.

### Claim 21

An AAV capsid protein comprising an insertion sequence of Formula III
R-X11-G-X12-X13-X14-X15 (III)
wherein X11 is an amino acid selected from A, D, E, I, N, V and S; X12 is an amino acid selected from E, H, L, M, S and V; X13 is an amino acid selected from F, H, L, P, V and Y; X14 is an amino acid selected from F, L and T; and X15 is an amino acid selected from D, H, K, L, M, Q, S and V.

### Claim 22 (depends on 21)

The AAV capsid protein of claim 21, wherein X1 is an amino acid selected from A, D, N and S.

### Claim 23 (depends on 21)

The AAV capsid protein of claim 21, wherein X2 is an amino acid selected from E, H, L, and V.

### Claim 24 (depends on 21)

The AAV capsid protein of claim 21, wherein X13 is an amino acid selected from F, H, P, and Y.

### Claim 25 (depends on 21)

The AAV capsid protein of claim 21, wherein X4 is F or L.

### Claim 26 (depends on 21)

The AAV capsid protein of claim 21, wherein X5 is an amino acid selected from K, L, M and V.

### Claim 27 (depends on 21)

The AAV capsid protein of claim 21, wherein the insertion sequence is selected from RSGHPFV, RNGEHFK, RDGHYLL, RNGEFFH, REGMPFL, RAGVHFV, RSGLHLM, RIGVHTS, RIGSVTQ, and RVGSLTD.

### Claim 28

An AAV capsid protein comprising an insertion sequence of Formula IV
X16-X17-G-H-X18-X19-X20 (IV)
wherein X16 is an amino acid selected from I, R, and L; X17 is an amino acid selected from D, G, Q, and S; X18 is an amino acid selected from I, P and Y; X19 is F or L; and X20 is an amino acid selected from H, L and V.

### Claim 29 (depends on 28)

The AAV capsid protein of claim 28, wherein X16 is L or R.

### Claim 30 (depends on 28)

The AAV capsid protein of claim 28, wherein X7 is an amino acid selected from P, Q and S.

### Claim 31 (depends on 28)

The AAV capsid protein of claim 28, wherein X9 is F or L.

### Claim 32 (depends on 28)

The AAV capsid protein of claim 28, wherein X20 is L.

### Claim 33 (depends on 28)

The AAV capsid protein of claim 28, wherein X20 is V.

### Claim 34 (depends on 28)

The AAV capsid protein of claim 28, wherein X18 is I or Y.

### Claim 35 (depends on 28)

The AAV capsid protein of claim 28, wherein the insertion sequence as described in FIG. 1, is selected from RSGHPFV, RDGHYLL, LQGHILL, and IGGHYLH.

### Claim 36

An AAV capsid protein comprising an AAV capsid protein comprising an insertion sequence of Formula V
R-X21-X22-X23-H-F-X24 (V)
Wherein X21 is an amino acid selected from A, N and S; X22 is an amino acid selected from D, E and G; X23 is an amino acid selected from E, L and V; and X24 is an amino acid selected from I, K, Q and V.

### Claim 37 (depends on 36)

The AAV capsid protein of claim 36, wherein X21 is A.

### Claim 38 (depends on 36)

The AAV capsid protein of claim 36, wherein X22 is D.

### Claim 39 (depends on 36)

The AAV capsid protein of claim 36, wherein X23 is E.

### Claim 40 (depends on 36)

The AAV capsid protein of claim 36, wherein X23 is L.

### Claim 41 (depends on 36)

The AAV capsid protein of claim 36, wherein X24 is Q.

### Claim 42 (depends on 36)

The AAV capsid protein of claim 36, wherein the insertion sequence is selected from RADLHFQ, RAGVHFV, RNGEHFK, and RSELHFI.

### Claim 43

An AAV capsid protein comprising an AAV capsid protein comprising an insertion sequence of Formula VI
X25-X26-X27-X28-X29-L-L (VI)
Wherein X25 is an amino acid selected from A, L, R, and Y; X26 is an amino acid selected from Q, E, D, T, K and F; X27 is an amino acid selected from G, Q, and A; X28 is an amino acid selected from H, G, T, V and D; and X29 is an amino acid selected from I, S, T and Y.

### Claim 44 (depends on 43)

The AAV capsid protein of claim 43, wherein X25 is L or R.

### Claim 45 (depends on 43)

The AAV capsid protein of claim 43, wherein X26 is an amino acid selected from Q, E, and D.

### Claim 46 (depends on 43)

The AAV capsid protein of claim 43, wherein X27 is G, or Q.

### Claim 47 (depends on 43)

The AAV capsid protein of claim 43, wherein X28 is H, or G.

### Claim 48 (depends on 43)

The AAV capsid protein of claim 43, wherein X29 is I, or Y.

### Claim 49 (depends on 43)

The AAV capsid protein of claim 43, wherein the insertion sequence is selected from LQGHILL, REQGYLL, RDGHYLL, YTGTSLL, AKAVTLL, and AFGDSLL.

### Claim 50

An AAV capsid protein comprising an insertion sequence of Formula VII
X30-X31-X32-X33-X34-S-S (VII)
wherein X30 is an amino acid selected from A, E, F, H, I, K, L, M, N, P, Q, S, T, V and Y; X31 is an amino acid selected from F, G, H, I, K, L, M, P, Q, R, S, T, and V; X32 is an amino acid selected from A, G, H, L, M, P, Q, S and V; X33 is an amino acid selected from E, G, H, I, P, Q, R, S, T and V; and X34 is an amino acid selected from D, G, I, L, M, N, R, S, T and V.

### Claim 51 (depends on 50)

The AAV capsid protein of claim 50, wherein X30 is V, Q or H.

### Claim 52 (depends on 50)

The AAV capsid protein of claim 50, wherein X31 is F, L or M.

### Claim 53 (depends on 50)

The AAV capsid protein of claim 50, wherein X32 is S, A or Q.

### Claim 54 (depends on 50)

The AAV capsid protein of claim 50, wherein X33 is G, H or S.

### Claim 55 (depends on 50)

The AAV capsid protein of claim 50, wherein X34 is G, V or M.

### Claim 56 (depends on 50)

The AAV capsid protein of claim 50, wherein the sequence is selected from VFSGVSS, QLQHGSS, HMASMSS, SSLTLSS, SVPSSSS, ITPSVSS, MTVQVSS, SHLSVSS, YPHQTSS, PQGGSSS, FRSSLSS, ISVSISS, ETQRGSS, IHPPSSS, TSAITSS, FKSQSSS, ASHSTSS, AVMRDSS, KGGETSS, VVSVTSS, LISIRSS, NSLGLSS, and HLAQNSS.

### Claim 57

An AAV capsid protein comprising an insertion sequence of Formula VIII
D-L-X35-X36-X37-X38-X39 (VIII)
wherein X35 is an amino acid selected from G, H, Q, S and T; X36 is an amino acid selected from K, N, P, R and S; X37 is an amino acid selected from H, L, R and S; X38 is an amino acid selected from D, K, R, S, T and V; and X39 is an amino acid selected from A, D, E, L and V.

### Claim 58 (depends on 57)

The AAV capsid protein of claim 57, wherein X35 is H or S.

### Claim 59 (depends on 57)

The AAV capsid protein of claim 57, wherein X36 is K, or R.

### Claim 60 (depends on 57)

The AAV capsid protein of claim 57, wherein X37 is L, or S.

### Claim 61 (depends on 57)

The AAV capsid protein of claim 57, wherein X38 is S, or V.

### Claim 62 (depends on 57)

The AAV capsid protein of claim 57, wherein X39 is A, or L.

### Claim 63 (depends on 57)

The AAV capsid protein of claim 57, wherein the sequence is selected from DLSRLSL, DLHKSVA, DLGNLKV, DLTPHKD, DLQRSDL, and DLGSRRE.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The AAV capsid protein of any of claims 1-63 wherein the AAV is AAV9.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The AAV capsid protein of any of claims 1-64 wherein the AAV is provided in SEQ ID NO: 1.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The AAV capsid protein of any of claims 1-65 wherein the insertion is between amino acid 588 and amino acid 589.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The AAV capsid protein of any one of claims 1-66, wherein 60 copies of the AAV capsid protein are assembled into the AAV capsid.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The AAV capsid protein of any of claims 1-67, wherein the AAV capsid protein is present in VP1, VP2, and VP3 of the AAV capsid.

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The AAV capsid protein of any of claims 1-68, wherein the AAV capsid protein is characterized by at least one of an increased transduction enrichment when measured in cardiovascular system in a subject when delivered to the subject systemically.

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The AAV capsid protein any of claims 1-69, wherein the AAV capsid protein further comprises an amino acid substitution comprising A589N or Q590P.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

An AAV capsid comprising an AAV capsid protein of any of claims 1-70.

### Claim 72 (depends on 71)

The AAV capsid of claim 71, wherein the AAV capsid is chimeric.

### Claim 73 (depends on 71, 72)

The AAV capsid of any of claims 71-72 that is isolated and purified.

### Claim 74 (depends on 71, 72, 73)

The AAV capsid of any of claims 71-73 formulated as a pharmaceutical formulation for systemic administration to treat a disease or a condition of the heart, the pharmaceutical formulation further comprising a pharmaceutically acceptable carrier.

### Claim 75 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The AAV capsid protein of any of claims 1-70 wherein the capsid protein is expressed in the cardiovascular system.

### Claim 76 (depends on 75)

The AAV capsid protein of claim 75, wherein the cardiovascular system comprises a cardiac cell.

### Claim 77 (depends on 75, 76)

The AAV capsid of any one of claims 75-76, wherein the cardiovascular system comprises a tissue that is selected from heart.

### Claim 78 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

A recombinant vector comprising a nucleic acid encoding the AAV capsid protein of any one of claims 1-70.

### Claim 79 (depends on 78)

A kit comprising:
a) a first vector comprising the recombinant vector of claim 78;
b) a second vector encoding a helper virus protein; and
c) a third vector comprising a therapeutic nucleic acid encoding a therapeutic gene expression product.

### Claim 80 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

A method of treating a disease or condition in a subject comprising administering a therapeutically effective amount of a pharmaceutical formulation comprising the AAV capsid protein of any one of claims 1-70.

### Claim 81 (depends on 80)

The method of claim 80, wherein the disease or the condition is a disease or a condition of a heart of the subject.

### Claim 82 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

A method of manufacturing a recombinant AAV particle from the AAV capsid of any one of claims 1-70, the method comprising:
a. introducing into a cell a nucleic acid comprising:
i.a first nucleic acid sequence encoding a therapeutic gene expression product;
ii.a second nucleic acid sequence encoding a recombinant viral genome comprising a capsid (Cap) gene modified to express the AAV capsid of any one of claims 1-70; and
iii.a third nucleic acid sequence encoding an AAV helper virus genome; and
b. assembling the recombinant AAV particle, the recombinant AAV particle comprising the AAV capsid encapsidating the first nucleic acid.

### Claim 83 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The AAV capsid protein of any of claims 1-70 wherein the AAV capsid protein is characterized by an increased transduction enrichment when measured in a tissue in a subject when delivered to the subject systemically.

### Claim 84 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The AAV capsid protein of any of claims 1-70 wherein the tissue is heart or cardiac tissue.

### Claim 85 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

An AAV particle comprising an AAV capsid protein of any of claims 1-70 and a viral genome.

### Claim 86

A peptide comprising an amino acid sequence selected from DLSRLSL, KLDPLLM, TPKHLLI, PDQRRTD, RHDPLVM, SHFSGRN, VSAVRDR, VGVPVVL, LLPSNYL, QLQITKE, LQVTSVL, and VFSGVSS.

### Claim 87

A recombinant adeno-associated virus (rAAV) comprising a capsid comprising any one of KGGLPFI, DLSRLSL, RSGHPFV, RADLHFQ, LQGHILL, KLDPLLM, IGGHYLH, RAGVHFV, LGGQILI, TPKHLLI, RNGEHFK, KDSIPFR, PDQRRTD, RHDPLVM, DNYTRHT, RSGLHLM, and TNSVRVV.
